A systematic review published in the journal Drug and Alcohol Dependence provides a detailed analysis of the findings of available clinical trials that investigated the effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder
Dermatologic Common (1% to 10%): Hair loss, rash, urticaria Postmarketing reports : Alopecia, angioedema, rash, urticaria Hair loss was reported in up to 5.8% of treated patients vs 1% placebo, with higher incidence associated with greater weight loss (20% or more)
doi: 10.1182/blood-2016-10-569186 [DOI] [PubMed] [Google Scholar] 77.Olesen J, Thomsen L, Lassen L, Olesen I
[19] Mounjaro for Type 2 Diabetes (Different Medication) Important: Mounjaro is a Different Drug If you have Type 2 Diabetes: Mounjaro (tirzepatide) is covered by Medicare Part D for T2D
It promotes normal, healthy brain activity, which supports normal nerve conduction and memory recall
As a result of our colleagues steadfast focus on helping people access and receive the care they need, we are well-positioned to help even more people and continue to generate strong, diversified growth in the coming years, said Witty in the press release